Edelman sets up biotech investor relations communication unit
Global public relations company Edelman has launched BIRO, which the group says provides "direct lines of communication to investment, scientific and health care professionals throughout the world." Michael Henman, a director at BIRO, said that "biotechnology entrepreneurs need both access to capital and commercial partners to help their businesses succeed," and claimed that BIRO can help them communicate effectively "with both these audiences." For further information on the new unit, contact Mr Henman or Nigel Breakwell on +44 (0)207 344 1200.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze